Th e insensitivity of hepatocellular carcinoma to chemotherapy is associated with alternation in tumor cell cycling. Th is current study was designed to investigate the impact of p silencing on the sensitivity of Human hepatocellular carcinoma HepG cells to cisplatin. HepG/CDDP/. and HepG/CDDP/. cells were induced by culture with increased doses of cisplatin and their sensitivities to cis-Diamine dichloroplatinum (CDDP) were determined by -(,-Dimethylthiazol--yl)-,-diphenyltetrazolium bromide (MTT). Th e impacts of p silencing on the cell cycling and P-gp expression were characterized by fl ow cytometry, RT-PCR and Western blot assays, respectively. Knockdown of p expression dramatically reduced the relative levels of p expression and the frequency of phase G, promoting cell cycling. On the other hand, knockdown of p expression signifi cantly up-regulated the expression of P-glycoprotein (P-gp) in HepG/CDDP/. cells, associated with the increased resistance of HepG cells to CDDP in vitro.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most malignant tumors worldwide [] , and is generally insensitive to anticancer drugs, which makes chemotherapeutic drug treatment diffi cult. It is estimated that  of patients who have received chemotherapeutic drugs rapidly developed drug resistance [, ] , which remains a diffi cult issue. Th erefore, discovery of mechanisms underlying the drug resistance is of great significance in the development of new strategies for the intervention of drug-resistant tumors. Th e development of drug resistance is attributed to the expression of drug-resistance related genes in tumor cells. A previous study has revealed that various cellular pathways may be involved simultaneously in the drug resistance [] . Increased repair of drug-induced DNA damage, blocked apoptosis, disruptions in the signal pathways, and alterations of factors involved in cell cycling contribute to the development of drug resistance [, ] . Th e cell cycle represents a series of tightly integrated events that allow the cells to grow and proliferate. The cyclin dependent kinases (CDKs) are important components of the cell cycle machinery, and are positively regulated by cyclins and negatively regulated by cyclin dependent kinase inhibitors (CDKIs) [] . p, one member of the cyclin-dependent kinase inhibitors (CDKIs) family, can prevent transition from the G to S phase by inhibiting CDK/-cyclinD mediated phosphorylation of retinoblastoma (Rb) [] . Induction of p over-expression can induce G-phase arrest through the TGF-β/Smad pathway [] . Indeed, down-regulated expression of p and related signaling that control G/S transition are frequently deregulated in human cancers, such as pituitary adenoma, myeloid disease, and gastric cancer [-] . Furthermore, loss of p expression is associated with the development of lymphoproliferative disorders and tumor formation [] . Consequently, targeting the cell cycle modulators, CDKI, may be an excellent opportunity for the treatment of hepatocellular carcinoma [] . Our previous study has shown that up-regulating p expression inhibits the progression of cell cycling and reverses the drug-resistant phenotype in drug-resistant HepG/ CDDP/. cells [] . Th is study is aimed at examining the impact of p knockdown on the progression of cell cycling and resistance to CDDP in CDDP-resistant HepG cells.
MATERIALS AND METHODS

Establishment of CDDP-resistant HepG cells
Human hepatocellular carcinoma HepG cells were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Science (CAS, Shanghai, China), and cultured in RPMI- medium supplemented with  fetal bovine serum (FBS, Invitrogen, Carlsbad, USA) . Th e cells were exposed to increased doses of cisplatin (, ., ., ., ., or . mg/L, Hospira, Unterach, Australia) for three months to generate a cisplatin-resistant HepG/CDDP/. cell line. Finally, the cells were maintained in . mg/L of CDDP in complete medium. In addition, HepG/CDDP/. cells were cultured in the presence of . mg/L CDDP (designated as HepG/CDDP/.) and were also used for experiments.
MTT assay
The sensitivity of HepG/CDDP/. and HepG cells to CDDP was tested by MTT assays. Briefl y, HepG/CDDP/. and HepG cells at  ×   per well were cultured in  FBS RPMI  medium in -well plates and treated in triplicate with . or  mg/L of CDDP for , , and  h, respectively. During the last h incubation, the cells were exposed to  μg/mL of MTT (-(,-dimethylthiazol--yl) ,-diphenyltetrazolium bromide, Sigma, St. Louis, USA). Th e resulting formaza in individual wells was dissolved with  μl of DMSO (Sigma, St Louis, USA) and measured at an absorbance of  nm using a VERSAmax spectrophotometer (Molecular Devices, Sunnyvale, CA). Th e cells cultured in medium alone were used as negative controls, and the IC for CDDP was calculated using the spass . software.
Transfection of siRNA
The -necleotide p-specific siRNA Y, Y, and Y duplexes or control siRNA-F were designed and chemically synthesized by Sangon Biotech (Shanghai, China), and their sequences are shown in Table  . To knockdown p expression, HepG/CDDP/. cells at ×  cells/well were incubated overnight in  FBS RPMI  medium in -well plates, and transfected in triplicate with different doses (- nM) of the -necleotide p specifi c siRNA Y, Y, and Y duplexes or control siRNA-F ( nM), respectively, using Lipofectamine TM , according to the manufacturers' instruction (Invitrogen). The levels of p mRNA transcripts were determined , , and  h later for evaluating the efficacy of p silencing by RT-PCR.
RT-PCR
HepG/CDDP/. cells were transfected with different doses of Y, Y, Y, or siRNA-F for , , and  h (as described above), and their total RNA was extracted, respectively, using the RNAiso TM Plus reagent, according to the manufacturers' instruction (TaKaRa Biotechnology, Otsu, Japan). Th e RNA samples ( μg/per group) were reversely transcribed into cDNA using the one-step RT-PCR kit (Takara Biotechnology), according to the manufacturer's instructions. The relative levels of p and Glyceraldehyde--phosphate dehydrogenase (GAPDH) mRNA transcripts were determined by PCR using the cDNA as the template and specifi c primers. Th e sequences of primers were sense -CGTTAAGTTTACGGCCAACG- and anti-sense -GGTGAGAGTGGCAGGGTCT- for p (bP), and sense -GAGCCAAAAGGTCAT-CATCTC- and anti-sense -AAAGGTGGAGTGGGT-GTC- for GAPDH (bp), respectively. The PCR reactions were performed in duplicate at °C for  min and then subjected to  cycles of °C for  sec, °C for  sec, and °C for  min, followed by an extension at °C for  min. The PCR products were resolved on agarosegel electrophoresis, and the relative levels of p mRNA transcript to GAPDH were determined using the Quantity One Software (Bio-Rad Laboratories, Beijing, China).
Cell cycle analysis
HepG/CDDP/. cells were transfected in triplicate with the Y or control siRNA-F ( nM) for , , and  h, respectively, and the cells were harvested, respectively. Subsequently, the cells ( ×   cells/tube) were washed with pre-cooled phosphate buffered solution (PBS) twice and fi xed with ice-cold  ethanol, followed by staining with  μg/mL of propidium iodide (PI, Sigma). The distribution of individual cell cycle phases was analyzed by flow cytometry using FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) for analysis of the DNA contents.
Western blot analysis
HepG/CDDP/. cells were transfected with Y ( nM) or siRNA-F for  h and the cells were harvested, respectively. Th e cells were lysed in cell lysis buff er for Western blot (Beyotime Institute Biotechnology, Shanghai, China) for  min on ice, and their protein concentrations were determined using the Pierce BCA reagents (Pierce, Rockford, USA), according to the manufacturers' instruction. Th e cell lysates were mixed with SDS-PAGE Sample Loading Buffer (×) and boiled for  min, followed by centrifuging. Th e cell lysates (μg/ lane) were separated by electrophoresis on  SDS-PAGE gel and transferred into PVDF membranes. Subsequently, the membranes were blocked with  non-fat milk in TBST with . Tween  for  h at room temperature, and then incubated overnight with  μg/ml of mouse-anti-human p monoclonal antibody and : diluted mouse-anti-human p-gp polyclonal antibodies (Santa Cruz Biotech, Santa Cruz, USA) at °C. After washing, the bound antibodies were detected with : diluted peroxidase-conjugated affinity-chromatography pure goat anti-mouse IgG (Santa Cruz Biotechnology) for  h at room temperature, and visualized using the enhanced chemiluminescence reagent (Santa Cruz Biotechnology) and Gel Doc TM XR + Imaging System (Bio-Rad Laboratories). Th e relative levels of p proteins to control GAPDH were analyzed using Image Lab TM . Software (MCM DESIGN, Copenhagen, Denmark).
Statistical analysis
Data are expressed as mean ± SD of each group. The difference among groups was analyzed by one way of analysis variance (ANOVA), and the difference between groups was determined by Student's t-test using Excel . software. A value of p<. was considered statistically significant. 
RESULTS
Establishment of CDDP-resistant
Knockdown of p expression in the CDDP-resistant HepG cells
To optimize the conditions, HepG/CDDP/. cells were transfected with - nM of control siRNA-F for  h. As shown in Figure  , transfection with  nM of siRNA-F for  h resulted in nearly  of cells carrying the siRNA-F. Next, we determined the efficacy of transfection with the p-specific siRNA on the p expression in HepG/ CDDP/. cells. HepG/CDDP/. cells were cultured overnight with compete medium in the presence of . mg/L of CDDP, and transfected with - nM of control siRNA-F or the p-specifi c siRNA Y, Y, or Y for - h, respectively. As shown in Figure A and B, while transfection with the siRNA-Y did not change the levels of p mRNA transcripts, transfection with the siRNA-Y obviously reduced the levels of p mRNA transcript by  in HepG/CDDP/. cells. More importantly, transfection with the siRNA-Y signifi cantly reduced the levels of p mRNA transcripts even at  h post transfection, and transfection with the siRNA-Y for  h dramatically minimized the p expression by . Similarly, transfection with the siRNA-Y inhibited the expression of p proteins in HepG/CDDP/. cells in vitro ( Figure C) . Hence, the siRNA-Y inhibited the expression of p in HepG/ CDDP/. cells in a dose and time-dependent manner. 
Knockdown of p expression promotes cell cycle progression in HepG/CDDP/. cells
To determine the impact of p silencing on the progression of cell cycling, HepG/CDDP/. cells were transfected with  nM of control siRNA-F or siRNA-Y for - h, respectively. Th e cells were harvested and their cell cycling was characterized by fl ow cytometry analysis ( Figure ) . Th e frequency of HepG/CDDP/. cells that had been transfected with control siRNA-F at G phase increased gradually with the extended culture time. In contrast, transfection with the siRNA-Y appeared to promote the progression of cell cycling in HepG/CDDP/. cells. Evidentially, the frequency of siRN-Y-transfected HepG/CDDP/. cells at G phase was reduced to . at  h post transfection and further decreased to . at  h post transfection (p<.). Th erefore, knockdown of p expression promoted the progression of cell cycling in HepG/CDDP-. cells in vitro.
Eff ect of p silencing on the expression of p-gp in HepG/CDDP/. cells
Th e increased levels of p-gp expression are associated with drug resistance in tumor cells [, ] . Finally, we examined the impact of p silencing on the expression of p-gp in HepG/CDDP/. cells. HepG/CDDP/. cells were transfected with  nM of siRNA-Y for - h, respectively, and the relative levels of p-gp proteins were determined by Western blot assays ( Figure ) . Apparently, the levels of p-gp expression increased with extended culture time in the Y-transfected HepG/CDDP/. cells, which may be associated with increased drug-resistance to CDDP in HepG cells.
DISCUSSION
Th e change in cell cycling is associated with drug resistance in tumor cells [] . Notably, CDKIs can inhibit the progression of cell cycling and rescue drug resistance in some tumors. In this study, we examined the eff ect of p silencing on the cell cycling and CDDP-resistance in HepG cells. We fi rst gen- These data extend our previous findings that upregulating p expression reverses the drug resistance of hepatocellular carcinoma cells [] . Given that promotion of cell cycling is associated with drug resistance in tumor cells, our fi ndings suggest that p may be a critical regulator of the development of drug resistance in HepG cells. Th e drug-resistant tumor cells usually maintain low concentrations of anti-tumor drug in the cell body, which is associated with an increase in the expression of transporter protein P-gp [] . Th e CDDP-resistant tumor cells are insensitive to cisplatin, which can bind to DNA, create adducts and break DNA strand, leading to inhibition of DNA replication. Th e CDDP-resistant tumor cells usually have suffi cient capacity to repair damaged DNA and maintain cell cycling [] . Th e cellular response to DNA damage can activate cell cycle checkpoints that serve as natural surveillance mechanisms for DNA integrity. Indeed, the CDDP-resistant HepG cells usually exhibit cell cycle arrest at G/G phase, a survival mechanism, which provides an excellent opportunity for the tumor cells to repair damaged DNA [] . We found that the frequency of HepG/CDDP/. cells in G/ phage increased gradually with the increased time in the presence of cisplatin, while the distribution of diff erent phases of cell cycle did not change significantly in stably CDDP-resistant HepG/CDDP/. cells. The consistent resistance may stem from decreased uptake of cisplatin and/or increased DNA repair [] . Our data are consistent with a previous observation of cell cycle arrest at phase G/G of human QGY/CDDP cells [] . Our previous study has demonstrated that up-regulation of p expression induces cell cycle arrest at G phase and inhibits the cell proliferative activity, reducing drug-resistance in HepG/CDDP/. cells [] . In the current study, we found that knockdown of p expression promoted cell cycling and increased CDDP-resistance in HepG/CDDP/. cells. Together, p is a negative regulator of cell cycle, associated with the development of CDDP-resistance in HepG cells [, ] . RNA interference (RNAi) is a powerful technique to silence gene expression post-transcriptionally, and it can inhibit the mRNA translation and promote mRNA degradation [] . Th e RNAi technique has been a promising therapeutic strategy [] . Chemically synthetic small interfering RNA (siRNA) is currently being evaluated as a potentially useful method for developing highly specific gene-silencing therapeutic reagents [] . We found that transfection with the Y p-specifi c siRNA eff ectively silenced p expression, but up-regulated the p-gp expression in the HepG/ CDDP/. cells. Apparently, treatment with the p-specific siRNA might not increase the sensitivity of cells to CDDP, suggesting that combination with other strategies, such as CDKI or other chemotherapeutic reagents targeting multiple points of cell cycle, may be more effective in rescuing the sensitivity of tumor cells to chemotherapy. In summary, our data indicated that knockdown of p expression by siRNA promoted cell cycling and increased CDDP-resistance, which was associated with up-regulated expression of P-gp in HepG/CDDP/. cells. Th erefore, our fi ndings demonstrated that p is a negative regulator of cell cycling, associated with the development of CDDP-resistance in HepG cells. Conceivably, p may serve as a therapeutic target in the treatment of hepatocellular carcinoma.
